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The current literature indicates that benzimidazole derivatives possess diverse
pharmacological activities, including antimicrobial (1-3), antiviral (4), antineoplastic (5),
analgesic (6), anti-inflammatory (7, 8), antihypertensive (9), and vasodilating activities
(10). Also, it is well-documented that triazole nucleus is associated with a variety of
pharmacological actions. Triazoles display pronounced antimicrobial (11-13), antitu-
bercular (14) and anti-inflammatory activities (15). Likewise, many fused heterocycles,
including triazoles, were found to possess different pharmacological effects (16).
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Some new derivatives of 1,2,4-triazolo[2,3-a]benzimida-
zoles were synthesized through the reaction of 1,2-di-
aminobenzimidazole with carbon disulfide. The result-
ing 1,2,4-triazolo[2,3-a]benzimidazole-2-thione intermedi-
ate reacted with one equivalent of the alkyl halide to
give the corresponding 2-alkylthio derivative 3a-g. The
latter were acylated to afford the 1-acyl-2-alkylthio-
-1,2,4-triazolo[2,3-a]-benzimidazole derivatives 4-10 in
good yields. Structures of the new compounds were ver-
ified on the basis of spectral and elemental methods of
analyses. Fourteen of the prepared compounds were tes-
ted for their possible antifungal activities. Most of the
tested compounds showed activity against Candida albi-
cans and Fusarium oxysporum comparable to that of flu-
conazole as a reference drug. Compounds 8a, 9a, and
10d are the most active ones against most of the fungi
used. Compounds 3e, 4d, 5d, 6d, 7d, 8c, 8d, 9d, and 10d
were tested for their anti-inflammatory and analgesic ef-
fects; most of these compounds showed potent and sig-
nificant results compared to indomethacin. Moreover,
ulcerogenicity and the median lethal dose (LD50) of the
most active compound 8d were determined in mice;
LD50 was found to be 275 mg kg–1 (i.p.).
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Commercially available non-steroidal anti-inflammatory drugs (NSAIDs) are wide-
ly used for reducing inflammation pain. The anti-inflammatory mechanism of NSAIDs
is due to reduction of prostaglandin synthesis by the inhibition of cyclooxygenase iso-
zymes (COX1 and COX2). Disruption of the cytoprotective prostaglandins by most of the
currently used NSAIDs results in a mechanism-based toxicity, mainly in the gastrointes-
tinal tract and kidney, which limits their therapeutic usefulness when long-term therapy
is required (17). So far, various substituted 1,2,4-triazolothiones and some of their con-
densed derivatives have been approached as anti-inflammatory agents (17). According-
ly, the present work aims at the design and synthesis of new 2-alkyl-1,2,4-triazoloben-
zimidazoles (3a-g) and 1-acyl-2-alkyl-1,2,4-triazolobenzimidazoles (4a-d, 5a-d, 6a-d,
7a-d, 8a-d, 9a-d, 10a-d). Synthetic pathways include different chemical modifications of
the structure of the parent compound 2, which might modulate the physicochemical
properties and consequently the biological activities of the target compounds. Moreover,
the study includes testing the target compounds for their expected antifungal along
with their analgesic-anti-inflammatory effects.
EXPERIMENTAL
Materials and equipment
Melting points were determined on an electrothermal melting point apparatus (Stu-
art Scientific, model SMP1, UK) and were uncorrected. Precoated silica gel plates (Kie-
selgel 0.25 mm, 60G F254, Merck, Germany) were used for thin layer chromatography.
The developing solvent system chloroform/methanol (9:1, V/V) was used (for com-
pounds 4b, 6d and 10d, a benzen/hexane mixture, 1:1, V/V). Spots were detected under
UV (254 nm) (Spectroline, model CM-10, USA). Compounds 3a-g and 4-10 were crystal-
lized from ethanol unless otherwise specified.
IR spectra (KBr discs) were recorded on a Shimadzu IR-470 spectrometer (Shima-
dzu, Japan). 1H NMR spectra were scanned on a Varian EM-360 L NMR spectrometer (60
MHz), (Varian, USA). Chemical shifts are expressed in d values (ppm) relative to tetra-
methylsilane (TMS) as an internal standard, using CDCl3, unless otherwise specified, as
a solvent. Elemental analyses were performed at the Unit of Microanalysis, Assiut Uni-
versity (Assiut, Egypt).
Most of the chemicals used were of commercial grade: o-phenylenediamine (Al-
drich, Germany), bromine (Aldrich), sodium cyanide, sodium hydroxide, potassium car-
bonate, potassium hydroxide, and gum acacia (El Nasr Pharm. Co., Egypt), hydroxyl-
amine sulphate (Aldrich), alkyl halides (Fluka, Switzerland) carrageenan (Sigma, USA),
carbon disulphide (Riedel-de Haën, Germany), and indomethacin (Nile Co., Egypt), Po-
tato Dextrose Agar (PDA) or Sabouraud Agar (SA) media were prepared in the Depart-
ment of Botany, Faculty of Science, Assiut University.
The starting material 1,2-diaminobenzimidazole 1 was prepared according to a re-
ported procedure (18) through the reaction of o-phenylenediamine with cyanogen bro-
mide (19), followed by amination using hydroxylamine-O-sulfonic acid (Scheme 1).
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Synthesis of 1,2,4-triazolo[2,3-a]benzimidazole-2-thione
To a stirred solution of 1,2 diaminobenzimidazole (10.0 g, 0.052 mol) in DMF (100
mL), CS2 (30 mL, 0.47 mol) was added (Scheme 1). The reaction mixture was refluxed for
16 h and the formed precipitate was filtered, washed with methanol and dried. The
product is insoluble in most organic solvents; hence, it was purified by dissolving in 5%
KOH. The alkaline solution was cooled in an ice bath, and then rendered acidic by addi-
tion of conc. HCl under stirring. The precipitate was filtered, washed with distilled wa-
ter and dried. The process of purification was repeated until constant melting point (Fig.
1, Table I).
Synthesis of 2-alkylthio-1,2,4-triazolo[2,3-a]benzimidazoles (3a–f)
To a suspension of compound 2 (9.5 g, 0.05 mol) and potassium carbonate (6.9 g,
0.05 mol) in dry acetone (100 mL), the appropriate alkyl halide (0.05 mol) was added.
The reaction mixture was stirred for 10-12 h at ambient temperature. Acetone was eva-
porated, the residue was triturated with water, and then extracted with chloroform
(3 ´ 15 mL). The chloroform extract was washed with water and dried with anhydrous
magnesium sulfate. Chloroform was evaporated and the residue was crystallized from
the appropriate solvent (Fig. 1, Tables I and II).
Synthesis of 2-phenacyl-1,2,4-triazolo[2,3-a]benzimidazole (3g)
Amixture of compound 2 (9.5 g, 0.05 mol) and a solution of phenacyl bromide (13.7
g, 0.07 mol) in dry ethanol (100 mL) was refluxed for 3 h in the presence of fused sodium
acetate (4.1 g, 0.05 mol). The separated solid was filtered, washed with water and dried.
The crude product was crystallized from ethanol as white crystals (Fig. 1, Table I).
Synthesis of 1-acetyl(tosyl)-2-alkylthio-1,2,4-triazolo[2,3-a]benzimidazoles (4a,d,
5a,d, 6a,d, 7a,d, 8a,d, 9a,d, 10a,d)
Acetyl or tosyl chloride (0.005 mol) was added to a suspension of the appropriate
2-alkylthio-1,2,4-triazolo[2,3-a]benzimidazole (3a–g) (0.005 mol) and anhydrous potassi-
um carbonate (0.69 g, 0.005 mol) in dry acetone (15 mL). The reaction mixture was stir-
red for 6-8 h at ambient temperature and acetone was then evaporated. Distilled water
was added to the residue and the formed precipitate was filtered, washed with water,
dried and crystallized from the appropriate solvent (Fig. 1, Table I).
Synthesis of 1-benzoyl(p-chlorobenzoyl)-2-alkylthio-1,2,4-triazolo
[2,3-a]-benzimidazoles (4b,c, 5b,c, 6b,c, 7b,c, 8b,c, 9b,c, 10b,c)
Benzoyl chloride or p-chlorobenzoyl chloride (0.004 mol) was dropped into a stirred
and ice-cooled solution of 2-alkylthio 1,2,4-triazolo[2,3-a]benzimidazole (3a–g) (0.004
mol) and sodium hydroxide (0.2 g, 0.005 mol) in water (15 mL). The reaction mixture
was stirred for 1 h. The separated solid was filtered, washed with water and dried. The
crude products were then crystallized from the appropriate solvents (Scheme 1, Table I).
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The synthesized compounds 2, 3b and 4-10 were tested for their antifungal activity
in vitro, in comparison with fluconazole as a reference drug using the standard agar disk
diffusion method (20) against six pathogenic, phytopathogenic or food poisoning fungal
species Trichophyton rubrum (Castellani) Sabouraud (AUMC 405), Candida albicans (Ro-
bin) Berkhout (AUMC 418), Microsporum canis Gruby (AUMC 241), Aspergillus flavus
Thom (AUMC 30), Fusarium oxysporum Schlechtendal (AUMC 210), and Penicillium ex-
pansum Link (AUMC 525). Fungal cultures were obtained from the Assuit University
Mycological Center (AUMC, Assiut, Egypt).
A spore suspension in sterile distilled water was prepared from 2-5 days old culture
of the test fungi growing on Potato Dextrose Agar (PDA) or Sabouraud Agar (SA) me-
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a Compounds 3b, 3c, and 5d crystallized from acetone, compounds 3d, 5b, 8b, and 10b from methanol, and
compounds 3f, 4c, 5c, 6c, 7c, 7d, 8c, and 9c from petrol ether.
Table I contd.
dia. The final spore concentration was 5 × 104 spores mL–1. About 15 mL of the growth
medium was placed into sterilized Petri dishes of 9 cm diameter and inoculated with 1
mL of the spore suspension. Plates were shaken gently to homogenize the inocula.
Sterile 5-mm filter paper disk (Whatman, UK) was saturated with 10 µL of the test
compound solution or fluconazole as a reference (100 µmol L–1 in DMSO) or DMSO as
negative control. Impregnated disks were then dried for 1 h and placed in the center of
each plate. The seeded plates were incubated at 28 ± 2 °C for 7 days. The radii of inhibi-
tion zones (in mm) of triplicate sets were measured and the results are given in Table III.
Anti-inflammatory and analgesic activity
Animals were housed in separate cages, 6 animals each, in temperature-controlled
rooms at 25 °C. Animals were allowed free access to food and water and maintained at a
12 h light/dark cycle. Work was conducted in accordance with the internationally ac-
cepted principles for laboratory animals use and care as found in the European Commu-
nity Guidelines.
For determination of anti-inflmmatory and analgesic activities, all test compounds
and reference drugs were suspended in 5% solution of gum acacia in normal saline. Sus-
pensions of the test compounds, reference drugs and 5% gum acacia-saline solution (ne-
gative control) were injected 1 mL each i.p.
The anti-inflammatory activity of nine representatives of the synthesized com-
pounds (3e, 4d-10d and 8c) was evaluated according to the method described by Winter
et al. (21), where a pedal inflammation in rat paws was induced by subplantar injection
of 0.2 mL carrageenan (0.2%) suspension in gum acacia into the right hind of the rats.
Male adult albino rats (100–120 g) were divided into groups, 11 groups altogether,
of five animals each. The rat paw thickness was measured with a Veriner caliper
(SMIEC, China) before and 1 h after the carrageenan injection to detect the carrageenan
induced inflammation. Each test compound at a dose of 10 mg kg–1 was injected i.p. to a
separate group of rats 1 h after carrageenan injection. Control group received the vehicle
(5% gum acacia), while the reference group received indomethacin, 10 mg kg–1.
The difference between the thicknesses of the two paws was taken as a measure of
edema. The measurement was carried out at zero, 1, 2, 3 and 5 h after injection of the test
compounds, reference drug, and the vehicle. The results of anti-inflammatory activity of
the test compounds and the reference drug are listed in Table IV.
The analgesic activity of compounds (3e, 4d, 5d, 6d, 7d, 8c, 8d, 9d and 10d) was de-
termined in mice using the hot plate method (22) in comparison with indomethacin. In
this method, the time taken by the mouse to lick its feet or to jump within the Plexiglas
cylinder placed on a hot plate surface (55 °C) was determined. This reaction time was
taken as the end point and the increase in hot plate latency was taken as the measure of
analgesic activity.
Male adult albino mice (20-25 g) were divided into eleven groups, of five animals
each. Nine test compounds and the reference drug were injected i.p. into mice at a dose
of 10 mg kg-1. Control group of animals was similarly treated with 5% gum acacia. The
reaction time was evaluated directly 0.5, 1, 2, 3 and 5 h of first injection. The results of
analgesic activity of the test compounds and indomethacin are listed in Table V.
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Gastric ulceration
Gastric lesions on the mucosa were determined using a Stereoscopic Microscope
(XSC-07, China). Observation of the gastrointestinal mucosa for the presence of lesions
following oral administration of graded doses of the test compounds as well as the refer-
ence drug was taken as an indication of ulcerogenic effects. Both the frequency of ulcer-
ation (expressed as the ratio of ulcerated animals) and the severity of ulceration (expres-
sed as ulcer index) were used for comparison of the tested compounds and indometha-
cin (23).
Six groups, of six male adult albino mice each, were fasted for 24 h. The tested com-
pounds and indomethacin were administered orally in doses of 10, 30 and 50 mg kg–1,
as suspensions in 5% gum acacia saline solution. After 6 h, the animals were killed, the
stomachs were removed and gastric lesions on the mucosa were determined using a ste-
reoscopic microscope. Ulcer was defined as at least one lesion 0.5 mm or more in length.
All lesions of more than 0.1 mm in length were summed to obtain the ulcer index and
the results were given in Table VI.
Determination of acute toxicity (LD50)
The median lethal dose (LD50) of compound 8d was determined in mice. Groups of
male adult albino mice, of five animals (25–30 g) each, were injected i.p. with graded do-
ses of the test compound. The percentage of mortality in each group of animals was de-




The starting material 1,2-diaminobenzimidazole (1) was prepared according to a re-
ported procedure through the reaction of o-phenylenediamine with cyanogen bromide
(18), followed by amination using hydroxylamine-O-sulfonic acid (19). Structure of com-
pound (1) was confirmed by comparison of its physical and spectral data with the re-
ported ones (19). 1H NMR spectrum of compound 1 showed two broad singlets at d 5.48
and 6.08 (two amino groups) besides a multiplet at d 7.30–8.10, equivalent to the four ar-
omatic protons as reported (19).
The key intermediate 1,2,4-triazolo[2,3-a]benzimidazole-2-thione (2) was prepared
by the interaction of 1,2-diaminobenzimidazole with CS2 in DMF (Fig. 1 and Table 1).
Structure of compound 2 was confirmed from its IR, 1H NMR as well as elemental anal-
ysis. IR spectrum showed a broad band at 3410 cm-1 (NH). 1H NMR spectrum revealed
the presence of a broad singlet at d 12.50 ppm (two NH groups) exchangeable with D2O
and a multiplet at d 7.33–8.13 corresponding to the four aromatic protons. MS spectrum
of compound 2 revealed the molecular ion peak M+ at m/z 190 (100%), corresponding to
the molecular mass of this compound. Also, the spectrum showed prominent peaks at
m/z 132 (66.2%) and m/z 90 (50.7%).
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2-Alkylthio-1,2,4-triazolo[2,3-a]benzimidazole derivatives 3a-g were synthesized by
the reaction of 1,2,4-triazolo[2,3-a]benzimidazole-2-thione (2) with one equivalent of res-
pective alkyl halide (Fig. 1 and Table I). The reaction afforded the S-alkyl derivatives
since the S-alkylation supersedes the N-alkylation due to higher nucleophilicity and
polarizability of the SH group rather than the NH one (25, 26). Structures of compounds
3a-g were confirmed by elemental analyses, IR and 1H NMR spectral data. IR spectra of
compounds 3a-g showed a broad band at 3410–3420 cm-1 (NH stretching) while their 1H
NMR spectra showed a broad singlet at d 12.00–13.00 ppm corresponding to NH, which
is exchangeable with D2O. Moreover, the S-alkyl substituents gave a pattern in the 1H
NMR spectra in accordance with the expected structures of these compounds (Table II).
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Table II. 1H NMR data of compounds 2–10
Compd.
No.
R R1 1H NMR (CDCl3, d ppm)
2a H H 7.33-8.16 (m, 4H, C6H4), 12.00 (hump, 2H, 2NH)
3aa CH3 H
2.75 (s, 3H, SCH3), 5.58 (hump, 1H, NH), 7.26-8.01 (m,
4H, C6H4)
3b C2H5 H
1.45 (t, 3H, SCH2CH3), 2.90-3.58 (q, 2H, SCH2CH3),
7.20-8.00 (m, 4H, C6H4), 12.00 (hump, 1H, NH)
3c CH2=CHCH2 H
3.87 (d, 2H, SCH2CH=CH2, J = 8.50 Hz); 5.00-5.58 (m,
2H, SCH2CH=CH2), 5.83-6.63 (m, 1H, SCH2CH=CH2),
7.25-8.00 (m, 4H, C6H4), 12.50 (hump, 1H, NH)
3d n-C3H7 H
1.07 (t, 3H, SCH2CH2CH3); 1.60-2.21 (m, 2H,
SCH2CH2CH3), 3.26 (t, 2H, SCH2CH2CH3), 7.26-8.03
(m, 4H, C6H4), 12.50 (hump, 1H, NH)
3e CH(CH3)2 H
1.53 (d, 6H, SCH(CH3)2, J = 8.50 Hz), 3.66-4.30 (m,
1H, SCH(CH3)2), 7.30–8.00 (m, 4H, C6H4), 12.50
(hump, 1H, NH)
3f C6H5CH2 H
4.56 (s, 2H, SCH2Ph), 7.16-8.00 (m, 9H, C6H4,
C6H5CH2), 13.00 (hump, 1H, NH)
3g C6H5COCH2 H
4.92 (s, 2H, SCH2COPh), 7.3-8.42 (m, 9H, C6H4,
C6H5COCH2), 12.36 (hump, 1H, NH)
4a CH3 CH3CO
2.70 (s, 3H, SCH3), 2.95 (s, 3H, NCOCH3), 7.30-8.84
(m, 4H, C6H4)
4b CH3 p-CH3C6H4SO2
2.46 (s, 3H, p-CH3C6H4SO2), 2.80 (s, 3H, SCH3),
7.30-8.55 (m, 8H, C6H4 and p-CH3C6H4SO2)
4c CH3 C6H5CO 2.61 (s, 3H, SCH3), 7.40-8.65 (m, 9H, C6H4, COC6H5)
4d CH3 p-ClC6H4CO
2.60 (s, 3H, SCH3), 7.30-8.30 (m, 8H, C6H4,
NCOC6H4Cl)
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Compd.
No.
R R1 1H NMR (CDCl3, d ppm)
5a C2H5 CH3CO
1.48 (t, 3H, SCH2CH3), 3.00 (s, 3H, NCOCH3),
3.06-3.53 (q, 2H, SCH2CH3), 7.30-8.00 (m, 4H, C6H4),
8.40-8.78 (m, 1H, C6H4)
5b C2H5 p-CH3C6H4SO2
1.50 (t, 3H, SCH2CH3), 2.41 (s, 3H, CH3), 3.05-3.63
(q, 2H, p-CH3C6H4SO2), 7.11-8.50 (m, 8H, C6H4,
p-CH3C6H4SO2)
5c C2H5 C6H5CO
1.38 (t, 3H, SCH2CH3), 2.84-3.33 (q, 2H, SCH2CH3),
7.16-8.66 (m, 9H, C6H4, COC6H5)
5d C2H5 p-ClC6H4CO
1.33 (t, 3H, SCH2CH3), 2.85-3.33 (q, 2H, SCH2CH3),
7.31-8.63 (m, 8H, C6H4, COC6H4Cl)
6a CH2=CHCH2 CH3CO
3.00 (s, 3H, NCOCH3), 3.92 (d, 2H, SCH2CH=CH2,
J = 8.50 Hz), 5.07-5.70 (m, 2H, SCH2CH=CH2),
5.82-6.47 (m, 1H, SCH2CH=CH2), 7.24-7.94 (m, 4H,
C6H4), 8.34-8.82 (m, 1H, C6H4)
6b CH2=CHCH2 p-CH3C6H4SO2
2.42 (s, 3H, CH3), 3.94 (d, 2H, SCH2CH=CH2, J = 8.50
Hz), 5.00-5.76 (m, 2H, SCH2CH=CH2), 5.85-6.57
(m, 1H, SCH2CH=CH2), 7.20-8.58 (m, 8H, C6H4,
p-CH3C6H4SO2)
6c CH2=CHCH2 C6H5CO
3.70 (d, 2H, SCH2CH=CH2, J = 8.50 Hz), 4.74-5.58 (m,
2H, SCH2CH=CH2), 5.72-6.44 (m, 1H, SCH2CH=CH2),
7.12-8.74 (m, 9H, C6H4, COC6H5)
6d CH2=CHCH2 p-ClC6H4CO
3.78 (d, 2H, SCH2CH=CH2, J = 8.50 Hz), 5.00-5.55 (m,
2H, SCH2CH=CH2), 5.74-6.50 (m, 1H, SCH2CH=CH2),
7.38-8.74 (m, 8H, C6H4, COC6H4Cl)
7a n-C3H7 CH3CO
1.12 (t, 3H, SCH2CH2CH3), 1.50-2.22 (m, 2H,
SCH2CH2CH3), 2.60-3.54 (m, 5H, NCOCH3,
SCH2CH2CH3), 7.12-8.74 (m, 4H, C6H4)
7b n-C3H7 p-CH3C6H4SO2
1.13 (t, 3H, SCH2CH2CH3), 1.52-2.32 (m, 2H,
SCH2CH2CH3), 2.45 (s, 3H, CH3), 3.34 (t, 2H,
SCH2CH2CH3), 7.24-8.64 (m, 8H, C6H4,
p-CH3C6H4SO2)
7c n-C3H7 C6H5CO
1.00 (t, 3H, SCH2CH2CH3), 1.35-2.15 (m, 2H,
SCH2CH2CH3), 3.06 (t, 2H, SCH2CH2CH3), 7.13-8.67
(m, 9H, C6H4, COC6H5)
7d n-C3H7 p-ClC6H4CO
1.00 (t, 3H, SCH2CH2CH3), 1.50-2.17 (m, 2H,
SCH2CH2CH3), 3.67 (t, 2H, SCH2CH2CH3), 7.33-8.14
(m, 7H, C6H4, COC6H4Cl), 8.34-8.74 (m, 1H, C6H4,
COC6H4Cl)
8a CH(CH3)2 CH3CO
1.50 (d, 6H, SCH(CH3)2 J = 8.50 Hz), 2.95 (s, 3H,
NCOCH3), 3.64-4.27 (m, 1H, SCH(CH3)2), 7.25-8.00
(m, 3H, C6H4), 8.37-8.74 (m, 1H, C6H4)
Table II contd.
On the other hand, reaction of compounds 3a-g with one of the different acyl
halides in the presence of either 5% aqueous NaOH solution (Schotten-Baumann reac-
tion) (27) or K2CO3 and acetone afforded 1-acyl-2-alkylthio-1,2,4-traizolo[2,3-a]benzimi-
dazole derivatives (4a,d, 5a,d, 6a,d, 7a,d, 8a,d, 9a,d, and 10a,d). The physicochemical
properties of these compounds are given in Table I. Structures of compounds (4a,d, 5a,d,
6a,d, 7a,d, 8a,d, 9a,d, and 10a,d) were established by IR and 1H NMR spectrometries as
well as elemental analyses. In IR spectra, disappearance of the absorption band at
3410–3420 cm-1, along with the appearance of a strong absorption band corresponding
to the carbonyl group (1680–1710 cm–1) confirmed the N-acylation. Also, disappearance
of the exchangeable broad singlet in the 1H NMR spectra is taken as an evidence for in-
troduction of the acyl group (Fig. 1). MS of 5d revealed the molecular ion peak M+ at m/z
41
B. G. Mohamed et al.: Synthesis of 1-acyl-2-alkylthio-1,2,4-triazolobenzimidazoles with antifungal, anti-inflammatory and analgesic
effects, Acta Pharm. 56 (2006) 31–48.
Compd.
No.
R R1 1H NMR (CDCl3, d ppm)
8b CH(CH3)2 p-CH3C6H4SO2
1.50 (d, 6H, SCH(CH3)2, J = 8.50 Hz), 2.44 (s, 3H,
CH3), 3.68-4.47 (m, 1H, SCH(CH3)2), 7.15-8.68 (m, 8H,
C6H4, p-CH3C6H4SO2)
8c CH(CH3)2 C6H5CO
1.37 (d, 6H, SCH(CH3)2, J = 8.50 Hz), 3.38-4.10 (m, 1H,
SCH(CH3)2), 7.18-8.74 (m, 9H, C6H4, COC6H5)
8d CH(CH3)2 p-ClC6H4CO
1.35 (d, 6H, SCH(CH3)2, J = 8.50 Hz), 3.37-4.00 (m, 1H,
SCH(CH3)2), 7.30-8.14 (m, 7H, C6H4, COC6H4Cl),
8.30-8.64 (m, 1H, C6H4, COC6H4Cl)
9a C6H5CH2 CH3CO
2.95 (s, 3H, NCOCH3), 4.53 (s, 2H, SCH2Ph), 6.95-8.00
(m, 8H, C6H4, SCH2C6H5), 8.05-8.76 (m, 1H, C6H4,
SCH2C6H5)
9b C6H5CH2 p-CH3C6H4SO2
2.45 (s, 3H, p-CH3C6H4SO2), 4.60 (s, 2H, SCH2Ph),
7.05-8.58 (m, 13H, C6H4, p-CH3C6H4SO2, SCH2C6H5)
9c C6H5CH2 C6H5CO
4.64 (s, 2H, SCH2Ph), 7.18-8.22 (m, 14H, C6H4,
SCH2C6H5, NCOC6H5)
9d C6H5CH2 p-ClC6H4CO
4.30 (s, 2H, SCH2Ph), 7.36-8.64 (m, 13H, C6H4,
SCH2C6H5, NCOC6H4Cl)
10a C6H5COCH2 CH3CO
2.83 (s, 3H, NCOCH3), 4.83 (s, 2H, SCH2COPh),
7.10-8.65 (m, 9H, C6H4, SCH2CO C6H5)
10b C6H5COCH2 p-CH3C6H4SO2
2.38 (s, 3H, p-CH3C6H4SO2), 4.87 (s, 2H, SCH2COPh),
7.15-8.45 (m, 13H, C6H4, p-CH3C6H4SO2, SCH2CO
C6H5)
10c C6H5COCH2 C6H5CO
4.64 (s, 2H, SCH2COPh), 7.17-8.30 (m, 14H, C6H4,
SCH2CO C6H5, NCOC6H5)
10d C6H5COCH2 p-ClC6H4CO
4.86 (s, 2H, SCH2COPh), 7.20-8.15 (m, 13H, C6H4,
SCH2CO C6H5, NCOC6H4Cl)
a Spectra were taken in DMSO-d6.
Table II contd.
356 (29.2%) corresponding to the molecular mass of this compound; CH 35ClNOS and a
peak at M++2 at (m/z 358, 12.5%) corresponding to CH 37ClNOS.
Antifungal activity
Results of antifungal activity are given in Table III. These results indicate that most
of the tested compounds were active against Candida albicans and their activity ranged
between 30 and 80% of that of fluconazole. Also, about half of the tested compounds
showed 35–94% of the antifungal activity of the reference drug against Fusarium oxyspo-
rum. On the other hand, compounds 6d, 8a, 9a, and 10d exhibited 70-80% of the anti-
fungal activity of fluconazole against Microsporium canis, and about 37% of the activity
of the drug against Trichophyton rubrum.
It is noteworthy that fluconazole was inactive against Aspergillus flavus and Penicil-
lium expansum, while compounds 4d, 6a, 8a, and 9a were active. These results can be ex-
plained in view of the reported data about the antifungal activity of azoles (28), which
indicate that they are active against dermatophytes such as Trichophyton, Epidermophyton,
and Microsporum spp., and yeasts such as Candida albicans. On the other hand, no data
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DMSO – – – – – –
Fluconazolea 20 18 10 – – 17
2a 8 – – – – 10
3ba 10 – – – – 14
4aa 10 – – – – –
4da 9 – – – 12 –
5aa 7 – – – – 10
5da – – – – – 16
6aa 6 – 0 7 6 –
6da 10 6 7 – – –
7aa – – – – – –
7da – – – – – –
8aa 10 8 7 9 7 7
8da 12 – – – – 8
9aa 16 6 8 8 7 6
9da 9 – – – – –
10aa – – – – – 12
10da 9 7 7 – 7 10
a c = 1 mmol L–1.
are mentioned in the available literature about their activity against Aspergillus flavus
and Penicillium expansum. The difference in the obtained antifungal activity between the
tested compounds and fluconazole might be attributed to their different three-dimen-
tional structures. This difference may affect their selectivity against the fungal cytochro-
me P-450 enzymes being responsible for the growth of fungi (28).
Anti-inflammatory and analgetic activity
Nine compounds 3e, 4d, 5d, 6d, 7d, 8c, 8d, 9d, and 10d, were selected for these tests
on the ground that seven of them contain the p-chlorobenzoyl substituent at N1 and the
other 2 contain either H or benzoyl moieties at N1 in order to investigate the crucial role
of the p-chlorobenzoyl substituent on anti-inflammatory and analgesic activities. Previ-
ous results were reported by Black et al. (29) and Kalgutkar et al. (30) indicating the vital
role of the p-chlorobenzoyl substituent for the activity of indomethacin and similar com-
pounds (cf. the activity of 3e and 8c). The tested compounds could be considered as
3-aza-indolotriazole derivatives and consequently we expected them to induce anti-in-
flammatory and analgesic effects.
The results for compounds 3e, 4d, 5d, 6d, 7d, 8d, 8d, 9d, and 10d, are presented in
Table IV, which revealed that within a 3 h interval most of the test compounds exhibited
anti-inflammatory activity comparable to that of indomethacin. On the other hand, only
compounds 6d, 7d, and 8d exhibited almost comparable results to those of indometha-
cin 5 h after injecting them, whereas compounds 9d and 10d showed only 85% and
85.9% of the activity of indomethacin. The delayed effect of compounds 6d-8d compared
to 4d and 5d can be explained as follows:
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Table IV. Inhibitory effects of test compounds upon carrageenan induced paw edema in rats
Compound
Edema inhibition (%)
Time after compound injection (h)
0 1 2 3 5
5% gum acacia – – – – –
Indomethacina 7.16 23.50 43.32 66.16 92.25
3ea 1.72 13.50 35.51 38.34 46.00
4da 1.97 6.25 35.76 63.65 43.00
5da 0.24 16.75 50.12 60.40 34.00
6da 0.98 13.50 48.11 63.40 90.80
7da 0.24 18.00 37.53 62.90 90.50
8ca 1.23 12.75 39.79 56.39 56.50
8da 2.22 18.75 43.32 63.65 91.25
9da 1.72 9.75 38.43 63.50 78.50
10da 0.74 11.75 37.53 61.65 79.25
a 10 mg kg-1 body mass.
The methyl and ethyl substituents on S at position 2 in compounds 4d and 5d most
probably undergo hydroxylation to primary and secondary alcohols respectively (31,
32). In the case of n-propyl (compound 7d) and isopropyl (compound 8d) substituents,
they are hydroxylated at the w-1 carbon atom (31, 32) to produce secondary and tertiary
alcohols, respectively. The allyl substituent (compound 6d) undergoes hydroxylation at
the allylic carbon atom (31) to produce a secondary alcohol. The initial alcohol metabo-
lites formed from these enzymatic w, w-1 and allylic oxidations are susceptible to further
oxidations to yield aldehydes (then acids) or ketones. Alternatively, the alcohol metabo-
lites may undergo glucuronide conjugation. The rate of the latter reaction is faster with
primary than secondary and tertiary alcohols due to steric factors. Taking these facts
into account, it is evident that the rates of metabolism of the C3-containing compounds
6d, 7d, and 8d will be delayed compared to those of compounds 4d and 5d.
On the other hand, the paw edema test revealed a marked decrease in anti-inflam-
matory activity upon replacement of the p-chlorobenzoyl moiety by H (3e) or benzoyl
(8c) substituents at N1. These results comply with the previously reported findings of
Black et al. (29) and Kalgutkar et al. (30).
Results for test compounds 3e, 4d, 5d, 6d, 7d, 8c, 8d, 9d, and 10d (Table V) after 3 h
revealed that the analgesic activity of all test compounds (except 3e and 8c) supersedes
that of indomethacin and this once again explains the importance of the p-chlorobenzoyl
substituent at N1. However, only compounds 6d, 7d, and 8d were more analgesic than
indomethacin after 5 h, which may be attributed to the different substituents at the S
atom in position 2 which might affect their metabolic pathways, and hence the different
analgesica was elicited as mentioned before (31, 32).
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Table V. Analgesic activity of test compounds in the hot-plate test in mice
Compound
Reaction time (s)b
Time after injection of test compound (h)
0.5 1 2 3 5
5% gum acacia 8.6 ± 0.74 8.1 ± 0.74 9.0 ± 1.0 8.0 ± 1.3 7.0 ± 0.2
Indomethacina 10.6 ± 0.8d 14.6 ± 0.8c 20.7 ± 2.2d 25.8 ± 1.1d 29.2 ± 0.5d
3ea 9.8 ± 0.2d 13.8 ± 1.3d 18.6 ± 2.2d 21.4 ± 1.9d 22.2 ± 0.9d
4da 11.8 ± 0.8d 17.8 ± 1.3d 21.6 ± 2.2d 26.6 ± 1.9d 22.2 ± 0.9d
5da 12.3 ± 0.8d 18.5 ± 0.7d 24.1 ± 1.1d 28.2 ± 1.4d 24.2 ± 1.5d
6da 14.3 ± 0.9d 21.0 ± 1.3d 26.3 ± 1.7d 32.3 ± 1.7d 38.1 ± 0.7d
7da 15.2 ± 1.8d 22.2 ± 0.1d 34.5 ± 0.9d 34.9 ± 0.9d 42.5 ± 0.4c
8ca 10.2 ± 0.8d 14.5 ± 0.7d 19.1 ± 1.1d 22.2 ± 1.4d 23.2 ± 0.5d
8da 15.5 ± 1.1d 23.1 ± 0.2d 36.8 ± 2.5d 45.3 ± 1.4d 48.6 ± 1.0d
9da 11.2 ± 0.7 15.1 ± 0.7 19.0 ± 1.1 28.0 ± 1.3 17.0 ± 0.2
10da 14.2 ± 1.8d 18.2 ± 0.1d 24.5 ± 0.9d 25.9 ± 0.9d 11.5 ± 0.4c
a 10 mg kg–1 body mass.
b Values are the mean ± SEM of five observations.
Significant difference vs. control value (Student t-test): c p < 0.05, d p < 0.01.
Ulcerogenic effects
Compound 8d that exhibited a potent analgesic and anti-inflammatory profile in
the pre-mentioned animal model was evaluated for its ulcerogenic effect on rats (23).
The compound showed a superior GI safety profile (17 and 50%) at oral doses 10 and 30
mg kg-1 respectively, when compared to indomethacin which was found to cause 67 and
100% ulceration, respectively (Table VI).
Acute toxicity
The median lethal dose (LD50) of the most active compound 8d was determined
(i.p.) in mice and was found to be 275 mg kg-1.
CONCLUSIONS
A number of 1-acyl-2-alkylthio-1,2,4-triazolo[3,2-a]benzimidazole derivatives were
synthesized and tested for their antifungal activities. Some of the tested compounds
showed activities comparable to that of fluconazole. Carrageenan induced paw edema
and hot-plate tests revealed potent anti-inflammatory and analgesic activities for seven
tested compounds. These compounds incorporate a p-chlorobenzoyl substituent at N1,
while compounds 3e (H) and 8c (benzoyl) elicited less potent anti-inflammatory and an-
algesic activities. These results are in agreement with the reported data. In addition, the
most active compound 8d showed a superior GI safety profile compared to indometha-
cin.
Acknowledgements. – The authors are greatly indebted to Dr. M. M. Hamdy, Department of
Pharmacology, Faculty of Medicine, Assiut University for his kind help for performing the anti-in-
flammatory and analgesic screening. Also, great thanks to Dr. Mohammed Hashem, Department of
Botany, Faculty of Science, Assiut University for his sincere help for carrying out the antifungal ac-
tivity tests.
45
B. G. Mohamed et al.: Synthesis of 1-acyl-2-alkylthio-1,2,4-triazolobenzimidazoles with antifungal, anti-inflammatory and analgesic
effects, Acta Pharm. 56 (2006) 31–48.
Table VI. Ulcerogenic effects of compound 8d in comparison with indomethacin
Compound Dose (mg kg–1) Ratio of ulcerated animals Ulcer index (mean ± S.E.)
Indomethacin
10 4/6 1.8 ± 0.1
30 6/6 2.1 ± 0.2
50 Not tested –
8d
10 1/6 1.10
30 3/6 1.2 ± 0.1
50 5/6 1.3 ± 0.1
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S A @ E T A K
Sinteza 1-acil-2-alkiltio-1,2,4-triazolobenzimidazola s antimikotskim,
protuupalnim i analgetskim u~inkom
BAHAA G. MOHAMED, ABDEL-ALIM M. ABDEL-ALIM i MOSTAFA A. HUSSEIN
Sintetizirani su novi derivati 1,2,4-triazolo[2,3-a]benzimidazola reakcijom 1,2-diami-
nobenzimidazola s uglji~nim disulfidom. Nastali 1,2,4-triazolo[2,3-a]benzimidazol-2-tioni
reagiraju s jednim ekvivalentom odgovaraju}eg alkil halida pri ~emu nastaju 2-alkiltio
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derivati 3a-g. Acilacijom produkata 3 dobiveni su derivati 1-acil-2-alkiltio-1,2,4-triazo-
lo[2,3-a]-benzimidazola 4-10 u dobrim iskori{tenjima. Strukture novih spojeva potvr|e-
ne su spektroskopskim metodama i elementarnom analizom. Ispitivano je antimikotsko
djelovanje 14 pripravljenih spojeva, uz flukonazol kao poredbenu tvar. Ve}ina testiranih
spojeva djeluje na Candida albicans i Fusarium oxysporum sli~no kao i flukonazol. Najak-
tivniji su bili spojevi 8a, 9a i 10d. Produkti 3e, 4c, 5c, 6c, 7c, 8b, 8c, 9c i 10c ispitani su na
protuupalno i analgetsko djelovanje, uz indometacin kao poredbenu tvar. Ve}ina spo-
jeva ima zna~ajno djelovanje. Najaktivniji spoj 8d testiran je na ulcerogenost. Srednja le-
talna doza (LD50) odre|ena je na mi{evima i iznosi 275 mg kg–1 (i.p.).
Klju~ne rije~i: 1,2-diaminobenzimidazol, hidroksilamin-O-sulfonska kiselina, 1,2,4-triazolo-[2,3-a]ben-
zimidazol, antimikotsko djelovanje, analgetsko djelovanje, protuupalno djelovanje
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University
Assiut-71526, Egypt
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